<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/001A9792-C636-4B75-A8D4-A3C1B55359DC"><gtr:id>001A9792-C636-4B75-A8D4-A3C1B55359DC</gtr:id><gtr:firstName>Ashok</gtr:firstName><gtr:surname>Venkitaraman</gtr:surname><gtr:orcidId>0000-0002-6876-2672</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001522"><gtr:id>6F194A43-425E-486C-8DE0-53DAF877752C</gtr:id><gtr:title>The Cambridge Molecular Therapeutics Programme (MRC Programme 2)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001522</gtr:grantReference><gtr:abstractText>Most new drugs that affect DNA repair or mitosis target an important group of proteins called enzymes, by blocking a particular region (the ?active site?) in them. However, human cells require multiple enzymes to function normally, and the ?active sites? of many of these are similar in structure. Therefore, drugs that block the active sites of enzymes are not sufficiently selective, leading to poor activity, and unwanted side effects in patients. We are developing new ways of making drugs, not by targeting the active sites of enzymes, but by disrupting interactions between proteins, which are necessary for cells to work correctly. We will not only devise methods to find the best targets to disrupt, but will also pioneer new methods to find drugs that disrupt these interactions, and find new ways to test the effect on human cells of the drugs we discover in this way, to evaluate their potential for further development. This work has the potential to transform the basic scientific research that helps us to understand human diseases, as well as the way new drugs are discovered and developed.</gtr:abstractText><gtr:technicalSummary>The MRC Cancer Unit s overarching strategic aim in its next quinquennium will be to translate improved understanding of early steps in epithelial carcinogenesis to interventions that improve the outcome of patients with epithelial cancer. A new programme in the Unit - the Cambridge Molecular Therapeutics Programme - brings together a unique interdisciplinary group of internationally recognized Cambridge science and scientists towards this end. It will provide a powerful new resource that is expected to have a far-reaching impact on the work of the Unit, and the Cambridge Cancer Centre.

The CMTP s primary aim in the next quinquennium will be to establish the scientific and technical know-how to target macromolecular interactions using small molecules. We will aim to determine: Which macromolecular interactions in biological pathways are most appropriate as drug targets (ie, Where to drug?); Through what methods can chemical tools against these targets be developed (ie, How to drug?).

A complementary but secondary aim will be to develop the appropriate preclinical models and clinical outlets for translation to the clinic. These studies will ask in what clinical settings agents targeting DNA repair or mitosis are most likely to be effective (ie, Who to drug?).</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3221386</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Chris Abell, David Spring</gtr:description><gtr:id>A8CE5FE1-199D-47C6-8FBE-333C608DF9F9</gtr:id><gtr:impact>Outputs: Grant income &amp;gt;&amp;pound;7M, several joint coauthored publications.

Multidisciplinary: Our MRC-funded team- protein biochemistry, structural biology, molecular cell biology, biophysics, assay development, computational modeling and structural chemistry, molecular imaging. Partners- organic synthetic chemistry</gtr:impact><gtr:outcomeId>NiLEDsEVQX8-1</gtr:outcomeId><gtr:partnerContribution>Our partners bring skills in organic synthetic chemistry.</gtr:partnerContribution><gtr:piContribution>This forms part of a multi-disciplinary collaboration to pioneer new approaches for the discovery and development of chemical tools that modulate new structural classes of molecular targets for chemical biology and therapeutics development. The MRC-funded research team in my laboratory contributes to work in protein biochemistry, structural biology, molecular cell biology, biophysics, assay development, computational modeling and structural chemistry, and molecular imaging.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Centenary Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A1C242B1-E91F-4D83-AE7A-76E249CAEEBE</gtr:id><gtr:impact>Around 100 pupils and teachers visited the unit, took part in hands-on activities and heard from our cancer researchers about their careers.

Increased engagement with local schools.</gtr:impact><gtr:outcomeId>ANG5xwBfPU4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Science Festival 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B120F10F-4361-47BE-ADD6-18262BA4B302</gtr:id><gtr:impact>Around 4,000 people passed through the Biology Zone, with many taking part in our activities, reading posters, etc.

Increased profile for unit, and engagement with a younger audience.</gtr:impact><gtr:outcomeId>CBNmRcqwbKf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GATES Scholarship- Fries</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>10278292</gtr:fundingRef><gtr:id>5A53491B-E978-43F0-953C-C91CF29FD088</gtr:id><gtr:outcomeId>tyB9GTPa1B3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>352371</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Aurora-A SDDI</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CF401B4A-72D3-452E-9983-9DBD1E586B32</gtr:id><gtr:outcomeId>oSRscWjrJAb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>294540</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust SDDI</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>D94967AF-63E4-44C9-8E30-F46D8B059686</gtr:id><gtr:outcomeId>GoYKiFmL1je</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CCC PhD Studentship - Campbell</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Cambridge Cancer Centre</gtr:fundingOrg><gtr:id>129AF20F-1EFE-4D36-A13D-9A23EF6D3129</gtr:id><gtr:outcomeId>JTvc8kNh2Yr</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship (Studentship) - S Ahmad</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Cambridge Cancer Centre</gtr:fundingOrg><gtr:id>E0723183-262C-4F61-818E-7F6F768B789D</gtr:id><gtr:outcomeId>skcNhBX8Z8g</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>897000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>49D7738B-4F56-422A-A61A-6F1B30892EE2</gtr:id><gtr:outcomeId>W5yXaWSwxfq</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academy of Medical Sciences</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>2183A24C-4578-42FE-8A11-DD9614236822</gtr:id><gtr:outcomeId>BBTnvpe8cxF</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Screening methods for peptides and nucleic acids which inhibit or block cell signalling pathways. These methods may be useful, for example, in identifying and characterising target proteins and also protein:protein interactions (PPI) sites for use as drug targets for the modulation of these pathways.

GB priority application 1426218.8 filed 13th November 2014
PCT patent application filed 12th November 2015 PCT/GB2015/053432</gtr:description><gtr:grantRef>G1001522</gtr:grantRef><gtr:id>FBFC2131-E927-4363-8999-76EA531A4469</gtr:id><gtr:impact>Unknown</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>57a1de8356db29.34900708</gtr:outcomeId><gtr:patentId>Ven-2505-10</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Upside down screen</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The Polo Box Domain (PBD) of Polo-Like Kinase 1 and anti-mitotic compounds targeting PBD including screening campaign and associated chemistry.</gtr:description><gtr:grantRef>G1001522</gtr:grantRef><gtr:id>C09A240A-762C-4228-BA0F-95B24157239A</gtr:id><gtr:impact>Unknown</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>57a0d09b679129.02246155</gtr:outcomeId><gtr:patentId>Ven-2245-08</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>PLK-1</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Improved methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods include those to identify a target protein that modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. The invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that bind to such a target protein and identification of a compound being a candidate modulator of said phenotype of a mammalian cell.

PCT Application PCT/AU2013/000110 7th February 2013
US national application 14/377,809.</gtr:description><gtr:grantRef>G1001522</gtr:grantRef><gtr:id>4E3E3E59-0C69-45ED-800B-03D9DC0B09FF</gtr:id><gtr:impact>Unknown</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>57a1df43aa33f8.14948364</gtr:outcomeId><gtr:patentId>Ven-2570-11</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Target within a target</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D48ACAFA-A3DF-4F4F-9832-22786EACA793</gtr:id><gtr:title>Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1333dc61a50bcdc0960fd1f4abc240f"><gtr:id>d1333dc61a50bcdc0960fd1f4abc240f</gtr:id><gtr:otherNames>Cassidy LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>5436a074935226.20290992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0736F1D-809F-43EE-B0B7-13E9C969DA2D</gtr:id><gtr:title>Diversity-oriented synthesis as a tool for identifying new modulators of mitosis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5966b8b69ea8c08c65551eb5584b90da"><gtr:id>5966b8b69ea8c08c65551eb5584b90da</gtr:id><gtr:otherNames>Ibbeson BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5436a0745dc985.18189042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0580F5E6-2EC6-4A21-BE7C-DA8A4E41F616</gtr:id><gtr:title>Specific inhibition of CK2a from an anchor outside the active site.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bd1718b7076fd687beb1551670bba26"><gtr:id>3bd1718b7076fd687beb1551670bba26</gtr:id><gtr:otherNames>Brear P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>585d36891a31c1.23428920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EFD3655-9B3D-480F-B0D0-93DEEF447AAB</gtr:id><gtr:title>Homeostatic control of polo-like kinase-1 engenders non-genetic heterogeneity in G2 checkpoint fidelity and timing.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24ec375abd205ba8e96b7e4e07a57e2b"><gtr:id>24ec375abd205ba8e96b7e4e07a57e2b</gtr:id><gtr:otherNames>Liang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5436a0730c63b3.24331542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>158A2CFA-6816-492A-B00A-2B923693B5C3</gtr:id><gtr:title>Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b77196dcbdac386045a7b78c93cc1468"><gtr:id>b77196dcbdac386045a7b78c93cc1468</gtr:id><gtr:otherNames>Perera D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d69859475d9.84005924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF5B7604-66B2-422F-AA0D-1230A16A61BD</gtr:id><gtr:title>Correlations in liquid water for the TIP3P-Ewald, TIP4P-2005, TIP5P-Ewald, and SWM4-NDP models.</gtr:title><gtr:parentPublicationTitle>The Journal of chemical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9606</gtr:issn><gtr:outcomeId>5a3272513951e1.13375016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFBD4FC8-AB36-42CF-93FE-8ACD14B9D67F</gtr:id><gtr:title>A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f8965e8e8465c924c0a035380d968b"><gtr:id>e0f8965e8e8465c924c0a035380d968b</gtr:id><gtr:otherNames>Jeyasekharan AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>pm_13318_28_24013206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E119453A-24AC-4A8B-8468-D313A2B65062</gtr:id><gtr:title>Double Strain-Promoted Macrocyclization for the Rapid Selection of Cell-Active Stapled Peptides.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8586c6b180b864a824ed1eec5eb01a4"><gtr:id>a8586c6b180b864a824ed1eec5eb01a4</gtr:id><gtr:otherNames>Lau YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56c71930991445.77820538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CD8D0F4-936B-417E-BF9C-F5AF4EEFF6C9</gtr:id><gtr:title>RNA Processing and Genome Stability: Cause and Consequence.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d29473af70d14c697b8cd9ba75e65"><gtr:id>a19d29473af70d14c697b8cd9ba75e65</gtr:id><gtr:otherNames>Wickramasinghe VO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>56d6b2a41f6f91.00301229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77A57C63-46F0-421A-9EDD-0E10D6CF53DE</gtr:id><gtr:title>Maximizing the biochemical resolving power of fluorescence microscopy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f542cf3e85d9fc356dcf95ba1bac77f"><gtr:id>4f542cf3e85d9fc356dcf95ba1bac77f</gtr:id><gtr:otherNames>Esposito A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5436a074bd82f0.77861645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D8F5A47-5127-4C55-ADA7-F592A1E92FDB</gtr:id><gtr:title>Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eaeb2e81353ecad12ce5da26aad67c13"><gtr:id>eaeb2e81353ecad12ce5da26aad67c13</gtr:id><gtr:otherNames>Venkitaraman AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5436a0736524f5.66150703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74451339-C417-48B3-9CBA-60B632B19ABE</gtr:id><gtr:title>Benchmarking the thermodynamic analysis of water molecules around a model beta sheet.</gtr:title><gtr:parentPublicationTitle>Journal of computational chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ef757e50484b76f4957c1c3dad0edcc"><gtr:id>1ef757e50484b76f4957c1c3dad0edcc</gtr:id><gtr:otherNames>Huggins DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0192-8651</gtr:issn><gtr:outcomeId>5a3272bd31d1e2.41932258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B204A8C-9566-4131-8807-94AC2EF3C2DF</gtr:id><gtr:title>Expression of LY6D is induced at the surface of MCF10A cells by X-ray irradiation.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6705d73eff6566ae63e3568b03e4702"><gtr:id>d6705d73eff6566ae63e3568b03e4702</gtr:id><gtr:otherNames>Kurosawa M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>pm_13318_28_23075424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BA74FE-0EEF-4C13-B8C0-D82EB5674F87</gtr:id><gtr:title>Investigating peptide sequence variations for 'double-click' stapled p53 peptides.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8586c6b180b864a824ed1eec5eb01a4"><gtr:id>a8586c6b180b864a824ed1eec5eb01a4</gtr:id><gtr:otherNames>Lau YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>5436a0733da501.21421209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE8E10C8-8ECF-44EB-8CC8-67A1494F8F1B</gtr:id><gtr:title>p53 shapes genome-wide and cell type-specific changes in microRNA expression during the human DNA damage response.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7de3df12752ce5f2ad67ba8b804a0bc"><gtr:id>f7de3df12752ce5f2ad67ba8b804a0bc</gtr:id><gtr:otherNames>Hattori H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>545e5a97e8b238.79182008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F21A342C-EB73-4B3D-8A7F-0505E43DF09B</gtr:id><gtr:title>High-resolution structure of the presynaptic RAD51 filament on single-stranded DNA by electron cryo-microscopy.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba4097716d2c886a85ad04e75c4aa8d2"><gtr:id>ba4097716d2c886a85ad04e75c4aa8d2</gtr:id><gtr:otherNames>Short JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5806228023f215.45405734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>412249E9-6127-4C76-AA2C-B0A101404D26</gtr:id><gtr:title>Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/405661fdcf6221fcaf0188903b88709e"><gtr:id>405661fdcf6221fcaf0188903b88709e</gtr:id><gtr:otherNames>Piccirillo SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>560cf4861241b4.30809774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9404E4F-432C-4C0D-B6E5-ABE570289D5F</gtr:id><gtr:title>Selective nuclear export of specific classes of mRNA from mammalian nuclei is promoted by GANP.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d29473af70d14c697b8cd9ba75e65"><gtr:id>a19d29473af70d14c697b8cd9ba75e65</gtr:id><gtr:otherNames>Wickramasinghe VO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5436a074086e53.17611449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0729147C-8FB7-4757-9D0C-928F24E88379</gtr:id><gtr:title>Impact of Alternative Splicing on the Human Proteome.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd588967543.61841113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ACB0B72-0A82-42A4-B422-EDB34B36049A</gtr:id><gtr:title>Regulation of constitutive and alternative mRNA splicing across the human transcriptome by PRPF8 is determined by 5' splice site strength.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d29473af70d14c697b8cd9ba75e65"><gtr:id>a19d29473af70d14c697b8cd9ba75e65</gtr:id><gtr:otherNames>Wickramasinghe VO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>560cf4852d82c6.89842347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17E58446-EF7D-4BED-919F-B872C737FB54</gtr:id><gtr:title>Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9984bc41af77236e9cd269aa01cfc43"><gtr:id>e9984bc41af77236e9cd269aa01cfc43</gtr:id><gtr:otherNames>Janecek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>585d54a14709f0.00635356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C09B264-322A-4EA6-A185-FD439675E982</gtr:id><gtr:title>Linear aliphatic dialkynes as alternative linkers for double-click stapling of p53-derived peptides.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8586c6b180b864a824ed1eec5eb01a4"><gtr:id>a8586c6b180b864a824ed1eec5eb01a4</gtr:id><gtr:otherNames>Lau YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>545e5a98179cc7.81091990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F874D40-C749-430E-B4C8-26B9EB93C619</gtr:id><gtr:title>Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f5b243c4d6b98f63194d44a82af0669"><gtr:id>0f5b243c4d6b98f63194d44a82af0669</gtr:id><gtr:otherNames>Laraia L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>560cf485d48c42.83271908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A691135-C6BC-4154-81EA-5536198AEA56</gtr:id><gtr:title>A-type lamins maintain the positional stability of DNA damage repair foci in mammalian nuclei.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1700422215cd472efef9d11f67e1c5b"><gtr:id>d1700422215cd472efef9d11f67e1c5b</gtr:id><gtr:otherNames>Mahen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13318_28_23658700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>264F260B-2BE7-4E60-89A4-5148D2653D79</gtr:id><gtr:title>Using a fragment-based approach to target protein-protein interactions.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/584952b12d6156f6729a395528a9a0f6"><gtr:id>584952b12d6156f6729a395528a9a0f6</gtr:id><gtr:otherNames>Scott DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>pm_13318_28_23344974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5C056B7-109E-428B-8123-275BACF62699</gtr:id><gtr:title>Human inositol polyphosphate multikinase regulates transcript-selective nuclear mRNA export to preserve genome integrity.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d29473af70d14c697b8cd9ba75e65"><gtr:id>a19d29473af70d14c697b8cd9ba75e65</gtr:id><gtr:otherNames>Wickramasinghe VO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>pm_13318_28_24074953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E31C59FE-34E1-45C4-8967-A97B5F891686</gtr:id><gtr:title>A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b366faa210eb4d0c0d06e001b09afa2"><gtr:id>5b366faa210eb4d0c0d06e001b09afa2</gtr:id><gtr:otherNames>Tan SLW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5a361bbe8a3ed7.53046529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7102C16A-D6C0-465E-8D1F-C56FEC4F386D</gtr:id><gtr:title>High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics.</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f5b243c4d6b98f63194d44a82af0669"><gtr:id>0f5b243c4d6b98f63194d44a82af0669</gtr:id><gtr:otherNames>Laraia L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn><gtr:outcomeId>54369fff59f1d9.42388833</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001522</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>